Loading…
← CockpitCompetitor Analysis › 300595.SZ Ovctek China, Inc. Class AOpen in the cockpit ↗

Ovctek China, Inc. Class A300595.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Hefei maker of orthokeratology lenses, overnight-wear contact lenses that slow myopia progression, with a growing chain of eye clinics.

Momentum strong 60
Mkt cap
$1.33B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$13.8M
20-day average traded
Fwd P/E
19.4×
forward earnings
ROIC−WACC
+0.1 pp
WACC 12.8%
Hurdle
-8 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥9.94
1D-2.8%
1W-4.2%
1M-1.5%
3M-15.4%
6M-25.2%
YTD-32.3%
1Y-39.7%
ATR %2.7%
52w lowhigh42.8% off high

What Ovctek China does

Hefei maker of orthokeratology lenses, overnight-wear contact lenses that slow myopia progression, with a growing chain of eye clinics.

Sells orthokeratology lenses, hard contact lenses worn overnight to reshape the cornea and slow myopia in children, through hospitals and optometry clinics, alongside lens-care products. It has also built its own chain of eye hospitals and clinics, so part of income now comes from eye-care services.

Products and services

  • Orthokeratology (OK) lenses
  • Lens-care products
  • Eye hospitals and optometry clinics

Customers

  • Children and teenagers with myopia
  • Eye hospitals and optometry clinics
  • Distributors

Where it sits in the supply chain

  • Health care
  • Eye-care devices
  • Orthokeratology lenses and optometry…

What could go right

  • Rising myopia among children
  • Eye-clinic chain expansion

What could go wrong

  • Dependence on OK lenses
  • Competition and pricing from new entrants

Moat: narrow (regulatory licence, distribution). Licensed OK-lens maker with hospital and clinic channels; device approval requirements slow new entrants.

Headquarters: Hefei, China · Employees: 3,752

Named competitors

Ovctek China at a glance

Size Ovctek China (300595.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.33B, the 1702nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.94 on 18 Nov 2026.

Performance Over six months the shares fell 25.2%, against -10.2% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 0.3% over the last twelve months (peer median +8.8%); the operating margin is 27.6% (peer median 6.8%).

Valuation It trades at 19.4× forward earnings against a peer median of 24.9× (6th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points above its cost of capital (12.8% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 90300595.SZ 76
Six months, rebased to 100: Ovctek China against the median of its 20 peers (local-currency closes).

Ovctek China financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.82BCN¥1.85BCN¥1.80BCN¥1.73BCN¥1.51B
Revenue growth—+3%+4%+14%—
Gross profitCN¥1.35BCN¥1.21BCN¥1.20BCN¥1.19BCN¥1.07B
EBITDAn/aCN¥813MCN¥835MCN¥864MCN¥805M
Net incomeCN¥440MCN¥480MCN¥572MCN¥667MCN¥624M
Free cash flowCN¥668MCN¥707MCN¥591MCN¥645MCN¥566M
Capital expenditureCN¥84.2MCN¥121MCN¥207MCN¥198MCN¥129M
Total debtCN¥196MCN¥308MCN¥367MCN¥345MCN¥298M

Quarterly statements and history in the cockpit →

Ovctek China competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%+20%688198688758300633STAANVCR688289CNMDPRCT3002986880503000492675ELNTNDM6881616880166849300406ENOVVITR300595.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Ovctek China is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×688198688758300633STAA688289CNMD3002986880502675688161688016ENOVVITR300595.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ovctek China is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%688198688758STAACNMD300298688050300049ELN6881616880166849300406ENOVVITR300595.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ovctek China is the large dot.

Ovctek China competitors and peer comparison

Head to head with its named competitors (300595.SZ vs 688050.SS vs 7780.T vs COO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ovctek China 300595.SZ$1.33B-25%0%28%19.4×8.3%
Eyebright Medical Technology (Beijing) 688050.SS$1.21B-16%+21%16%23.9×10.3%
Menicon 7780.T$944M+26%+6%9%20.9×n/a
Cooper Companies (The) COO$11.6B-2%+5%19%13.4×9.4%

How Ovctek China compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ovctek China against its 20 peers (data as of 18 Nov 2026)
Measure300595.SZPeer medianRank in peer set
1-month return-1.5%+0.3%10th lowest of 21
6-month return-25.2%-10.2%6th lowest of 21
Distance from 52-week high-42.8%-32.6%5th lowest of 21
Revenue growth (TTM)+0.3%+8.8%6th lowest of 21
Operating margin27.6%6.8%5th highest of 21
Forward P/E19.4×24.9×6th cheapest of 18
Growth the price implies (Req g, 7 yrs)8.3%11.0%5th least demanding of 15
Growth delivered (Del g)+16.5%+12.2%7th highest of 15
Hurdle (Req g minus delivered)-8.1 pp-3.8 pp6th least demanding of 15
ROIC minus cost of capital+0.1 pp+0.6 pp10th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%

Questions

Who are Ovctek China's main competitors?
Named competitors: Eyebright Medical (688050.SS), Menicon (7780.T), Cooper Companies (COO). The cockpit's measured peer set (industry) also includes Beijing Balance Medical Technology (688198.SS), Suzhou Sepax Technologies (688758.SS), Sonoscape Medical (300633.SZ), STAAR Surgical (STAA), NovoCure (NVCR), Sansure Biotech (688289.SS).
Is Ovctek China expensive compared with its peers?
On forward p/e it trades at 19.4× against a peer median of 24.9×, 6th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Ovctek China stock performed?
Over six months to 18 Nov 2026 the shares returned -25.2% against -10.2% for the median peer; over one year -39.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.